Skip to content
DataLookout
Menu

AspireNCT06617429

Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)

StatusTerminated
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 20 versions: 17 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: Lack of efficacy Show 4 more changesShow less
    • Study completion date changed from estimate of Nov 2027 to Oct 30, 2026
    • Eligibility criteria expanded, about 14 words
    • Secondary endpoints: details revised at 1 of 9 entries
    • Site details revised at 6 of 28 sites
  2. Minor Primary completion date changed from estimate of Jul 2026 to Jul 10, 2026v19
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 120 to confirmed 129
    • Study sites: 31 to 28
    • Study title expanded, about 2 words
    v15
  4. Minor Study sites revised (31)v14
  5. Minor Study sites revised (31)v13
Show 11 earlier versionsHide 11 earlier versions
  1. Minor Study sites revised (31)v12
  2. Minor Study sites revised (31)v11
  3. Minor Study sites: 30 to 31v10
  4. Minor Study sites: 29 to 30v9
  5. Minor Study sites revised (29)v8
  6. Minor Study sites: 28 to 29v7
  7. Minor Eligibility criteria shortened, about 77 words
    • Secondary endpoints: 6 to 9
    • Study sites revised (28)
    v6
  8. Minor Study sites revised (28)v5
  9. Minor Study sites: 29 to 28v4
  10. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 29
    • Start date changed from estimate of Dec 2024 to Dec 3, 2024
    v3
  11. Minor Study sites: 0 to 1v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change from Baseline in Bayley-4 Cognitive Raw Score Without Caregiver Input at Day 338
Timeframe: Baseline, Day 338

Secondary (9)

Net Response in Multidomain Responder Index (MDRI)
Change from Baseline in ABC-C Hyperactivity/Noncompliance Subscale Score at Day 338
Change from Baseline in Bayley-4 Receptive Communication Raw Score at Day 338
Change from Baseline in Angelman Severity Assessment (ASA) Sleep Rating Raw Score at Day 338
Change from Baseline in Vineland Adaptive Behavior Scales-3 (Vineland-3) Receptive Communication Raw Score at Day 338
Show 4 moreShow less
Change from Baseline in Vineland-3 Expressive Communication Raw Score at Day 338
Change from Baseline in Bayley-4 Gross Motor Raw Score at Day 338
Change from Baseline in ASA Gross Motor Rating at Day 338
Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), Severity of AEs and Relationship to Investigational Drug, Procedure, and Premedication

Arms and interventions

GTX-102Experimental

Participants will receive GTX-102 via lumbar puncture (LP) during both the double-blind and open-label period

Sham-LP then GTX-102Sham comparator

Participants will receive sham procedure during the double-blind period and then will receive GTX-102 via LP during the open-label period

Drugs: GTX-102

Procedures: Sham-LP

Sites

28 sites in 6 countries

United States 14, Spain 4, Germany 3, Japan 3, Canada 2, Poland 2